A 72-year-old woman with myasthenia gravis is admitted for acute exacerbation with severe generalized weakness, ptosis, and respiratory compromise (FVC 1.2 L, RR 28/min). She is on pyridostigmine 60 mg QID at home. In the ICU, she is intubated and sedated. On day 3, her physicians plan to wean sedation and assess her neuromuscular status. Which of the following is the most appropriate strategy regarding her cholinergic medication during ICU management?